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Summary cutaneous telangiectasia and hemorrhage from nasal
and gastrointestinal vascular beds. Nosebleeds (epi-
To identify mutations that cause hereditary hemorrhagic
staxes) are usually the earliest clinical symptom, muco-
telangiectasia (HHT, or Rendu-Osler-Weber syn-
cutaneous telangiectases develop in approximately one-
drome), clinical evaluations and genetic studies were
third of cases at age õ30 years, whereas anemia due
performed on 32 families. Linkage studies in four of
to gastrointestinal bleeding occurs later in life. Twenty
eight families indicated an endoglin (ENG) gene muta-
percent of affected individuals (Plauchu et al. 1989) de-
tion. ENG sequences of affected members of the four
velop pulmonary arteriovenous malformations
linked families and probands from the 24 small families
(PAVMs), which may result in hypoxemia, and para-
were screened for mutations, by Southern blot analyses
doxical embolism.
and by cycle sequencing of PCR-ampliﬁed DNA. Seven
The vascular pathology of HHT may be distinguished
novel mutations were identiﬁed in eight families. Two
histologically from other forms of hereditary telangiec-
mutations (a termination codon in exon 4 and a large
tases and vasodilatation (Braverman et al. 1983, 1990;
genomic deletion extending 3 of intron 8) did not pro-
Shovlin and Scott 1996). However, no speciﬁc ultra-
duce a stable ENG transcript in lymphocytes. Five other
structural or histochemical features have been observed
mutations (two donor splice-site mutations and three
to account for the vascular pathology. The small HHT
deletions) produce altered mRNAs that are predicted to
mucocutaneous telangiectasia are focal dilatations of
encode markedly truncated ENG proteins. Mutations in
postcapillary venules in the dermal upper-horizontal
other families are predicted to lie in ENG-regulatory
plexus, with abnormal stress ﬁbers in the venule peri-
regions or in one of the additional genes that may cause
cytes (Braverman et al. 1990). More complex vascular
HHT. These data suggest that the molecular mechanism
abnormalities, such as arteriovenous malformations, ex-
by which ENG mutations cause HHT is haploinsufﬁ-
hibit direct communication between dilated arterial and
ciency. Furthermore, because the clinical manifestation
venous elements and are devoid of intervening capillary
of disease in these eight families was similar, we hypoth-
beds. The lesions appear to progress by remodeling
esize that phenotypic variation of HHT is not related
(Clark and Clark 1940) via recruitment of mural cells
to a particular ENG mutation.
and involvement of further vascular segments.
Molecular-genetic analyses of HHT have identiﬁed
Introduction disease loci on chromosomes 9 and 12, and at least one
other HHT locus is predicted (Piantanida et al. 1996).
Hereditary hemorrhagic telangiectasia (HHT, or Rendu-
The disease gene on chromosome 9q encodes endoglin
Osler-Weber syndrome) is an autosomal dominant dis-
(ENG; McAllister et al. 1994), which is expressed pre-
order characterized by aberrant vascular development
dominantly on endothelial cells as a heavily glycosylated
(Rendu 1896) and has an incidence of Ç1/10,000 (Plau-
disulﬁde-linked dimer that binds TGF-b1 and -b3
chu et al. 1989). Clinical manifestations include muco-
(Cheifetz et al. 1992). ENG associates with the TGF-b
signaling receptors (Yamashita et al. 1994; Zhang et al.
1996) and modiﬁes TGF-b1 signal transduction (Lastres
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1997.
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To better understand the relationship between ENG dom hexanucleotide labeling (Boehringer-Mannheim)
(Ausubel et al. 1989). Clone 104 contained the 3 exonsmutations and the incidence of PAVMs and to elucidate
the mechanism by which ENG mutations cause HHT, of ENG and a novel CA repeat described below. P1
rearrangements were excluded by both analysis of geno-we studied 32 HHT families. ENG sequences were
screened for defects in probands from 28 families; and mic DNA and agreement with the AK1 fragment sizes
predicted by the GenBank sequence.in 8 families a causal mutation was identiﬁed. Affected
individuals from these eight families exhibited compara-
Linkage Analysesble clinical features of HHT, indicating little effect of
genotype on the variable phenotype of HHT. Further- Six polymorphic loci, ordered D9S60/D9S315/AK1/
ENG/SPTAN/D9S61, span 2 cM on chromosome 9qmore, two of the mutations demonstrated a marked re-
duction in ENG transcription from the mutant allele, (Shovlin et al. 1995a). Linkage studies were performed
as described elsewhere (Shovlin et al. 1994a), by use ofthereby providing information on the molecular mecha-
nism of HHT pathogenesis. published sequences to amplify D9S60, D9S315, D9S61
(GenBank), and AK1 (Puffenberger and Francomano
1991). Two novel CA repeats associated with P1 clonesMaterial and Methods
containing ENG and SPTAN were identiﬁed in P1
Clinical Evaluations clones by use of Quick Light (Life-Codes) probes and
protocols. The primer sequences, derived by vectorette-All studies were performed with the approval of local
mediated PCR (Edwards et al. 1991) of P1 clones, werecommittees for research on human subjects. Thirty-two
ENG-CA 5atctcagctactgtgagctgaggca and 5aagccccac-study families of northern-European descent were iden-
ggacagcactgga and SPTAN-CA 5accgtgttagccaggatg-tiﬁed when one affected member was referred to a ter-
gtcttga and 5tatccccagcactttgcatggtattt. ENG-CA hastiary-care hospital (Hammersmith Hospital, London)
four alleles, size 215–221 bp and PIC .35; SPTAN-CAfor therapy. Referrals were usually for PAVMs; ﬁve pro-
ampliﬁed three alleles, size 185–193 bp and PIC .26.bands were referred for other HHTmanifestations. Clin-
ical evaluations, including history, physical examina-
ENG Primer Sequencestion, and portable oximetry to screen for PAVMs
All ENG cDNA primers (C1–C19) were derived from(Chilvers et al. 1990), were performed on all available
the published GenBank (NIH sequence databases) ENGfamily members of each proband, by C.L.S. Additional
cDNA sequence (GenBank accession number X72012)medical history was obtained from patient records. Di-
and are described in the legend to ﬁgure 1. Intronicagnostic criteria for disease status have been described
primers (E1 forward–E14 reverse; ﬁg. 2) were derivedelsewhere (Shovlin et al. 1994a).
either from the work of McAllister et al. (1994) or by
Genetic Analyses sequencing templates derived from the P1 clones, includ-
ing subclones, long-PCR products, inverse-PCR tem-Genomic DNA was derived from peripheral blood, as
plates (Ausubel et al. 1989), vectorette (‘‘bubble’’)-medi-described elsewhere (Shovlin et al. 1994a). mRNA was
ated PCR (Edwards et al. 1991), and alu-exon PCRprepared from Epstein-Barr virus (EBV)–transformed
products, by use of alu primers complementary to thelymphoblastoid lines (Ausubel et al. 1989) or from
reverse 5 and forward 3 of the Alu consensus sequence:buffy-coat leukocyte preparations from 10 ml of fresh
Tagle3 (gatcgcgccactgcactcc) and alu450 (aaagtgctggga-blood by use of RNAzolTM (Cinna Biotecx).ENG cDNA
ttacagg).was transcribed from these templates by Moloney mu-
rine leukemia virus reverse transcriptase (Gibco BRL)
ENG-Mutation Screens(Ausubel et al. 1989) and by SuperscriptIITM (Gibco
Southern blot analyses were performed by use of ge-BRL), by use of an oligo (dT)14 primer, ENG-speciﬁc
nomic DNA digested with EcoRI, HindIII, and TaqI andprimers, and, for family I, RKdt (ccgcgaattcgg-
were probed either with 32P-labeled ENG 18A cDNAtacc[dT]17).
(Gougos and Letarte 1990) (kindly supplied by Michelle
Genomic Characterization of ENG Letarte) or with a 32P-labeled C1/C12 PCR product.
PCR products spanning exons or groups of exons wereFour clones containing ENG were identiﬁed from a
pAd10sacBII (‘‘P1’’) library of human genomic DNA screened for mutations, by manual cycle sequencing.
ENG sequences were ampliﬁed from genomic DNA or(DuPont-Merck), as described elsewhere (Shovlin 1996).
Clone 22 contained the entire coding sequence of ENG cDNA templates by use of a ﬁnal 25-ml PCR reaction
composed of 0.6 units of rTth DNA polymerase XLand the adjacent adenylate kinase 1 gene (AK1). The
clone was characterized further by Southern blots using (Perkin Elmer), 85 mM potassium acetate, 25 mM tric-
ine pH 8.7, 8% glycerol, 1% dimethylsulfoxide (XLeither PCR-ampliﬁed ENG exons (Saiki et al. 1988) la-
beled with 32P adCTP (Du Pont/NEN) by PCR or ran- buffer II; Perkin Elmer), 1 mM magnesium acetate, and
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Figure 1 ENG cDNA structure and the exons that encode it. The location of oligonucleotide primers used to amplify ENG sequences
are indicated (arrows). The number and order of exons are as described by McAllister et al. (1994) and our unpublished data; for each exon,
the last nucleotide is numbered according to GenBank accession number X72012. The variably retained intron (13A) between exons 13 and
14 (shaded) encodes the ENG-S form (Bellon et al. 1993). Primers are as follows (start nucleotide‘‘c’’ [if sequence is complementary] length
[in nucleotides]): C1 (63;26), C2 (257;24), C3 (282;23), C4 (534;c;28), C5 (604;28), C6 (724;25), C7 (775;c;24), C8 (1149;24), C9
(1225;c;25), C10 (1342;c;23), C11 (1328;24), C12 (1441;c;25), C13 (1552;24), C14 (1650;c;25), C15 (1759;c;25), C16 (2178;c;26),
C17 (2213,28), C18 (2463;c;22), C19 (2591;c;25), and C20 (2567;23).
0.2 mM each dNTP. The enzyme was added in a manual (pGEM-SZ; Promega). Sequence analyses were per-
formed by use of the GCG software package (program‘‘hot start’’ after the ﬁrst denaturation step (20 s at
94C). The subsequent 30 cycles were 94C for 10 s and manual for the Wisconsin Package, version 8).
68C for 1–5 min (according to product length). For
ampliﬁcation of cDNA reverse transcribed from ENG Results
mRNA (reverse-transcription PCR [RT-PCR]), the reac-
tion included a ﬁrst cycle of 94C for 1 min and 68C Since HHT can be caused by mutations in more than
one gene, linkage analyses were initially performed infor 10 min. Exons 1 and 3 required an annealing step
of 58C, including, for exon 1, a step-down procedure the study families whose size was sufﬁcient to provide
information. Linkage studies excluded an ENG muta-from an initial temperature of 68C (Hecker and Roux
1996). The quality of PCR-ampliﬁed products was as- tion in four families (families S, T, V, and Y; LOD score
õ01.32); HHT in four families (A, B, F, and W; LODsessed by agarose-gel electrophoresis. The CyclistTM Taq
DNA sequencing kit (Stratagene) was used to sequence score ú1.32) was linked to the ENG locus on chromo-
some 9 (table 1). DNA samples from probands of the 42 ml of PCR products directly: gel puriﬁcation was re-
quired only for early Taq PCR products in unnested families whose HHT was linked to chromosome 9 and
from probands from the remaining 24 small HHT fami-sequencing reactions or to separate wild-type and mu-
tant alleles, as an alternative to T-vector cloning lies were studied further.
Figure 2 Schematic of ENG spanning 35 kb, and expanded view of the 11 kb spanning exons 4–14. Restriction-enzyme sites are indicated
as follows: B Å BamHI; X Å XhoI; H Å HindIII; E Å EcoRI; x Å XbaI; P Å PstI; and b Å BglI. Arrows represent the position and orientation
of the alu elements ﬂanking exon 8. Exons were ampliﬁed with intronic primers E2 forward and reverse, E4 forward and reverse, E5 forward,
E6 forward and reverse, E7 forward and reverse, E10 reverse, E11 forward and reverse, E12 forward and reverse, and E13 forward, described
by McAllister et al. (1994). In addition intronic primers E1 forward (ccagccccttctctaaggaa), E1 reverse (tccccaccctgggtccctggaca), E3 forward
(aacctatacaaatctgact), E3 reverse (tgacagtaggacttcccat), E5 reverse (tctcgggntggggactagtgtca), E8 forward (gccgcctggcctgcctctgcta), E8 reverse
(tgagcnngaggggcaggagtt), E9 forward (aatggctgtgacttgggacccctg), E9A reverse (gacaacagctggtcctgatac), E9B reverse (aggagtttcccgaggcctgctccca),
and E14 reverse (aatgtcactgcccttctcccagc) were used. Exons 9A, 9B, and 10 were ampliﬁed by use of E9 forward/E10 reverse (or, for exon 10,
by use of C13/E10 reverse), and exons 13, 13A, and 14 were ampliﬁed by use of E13 forward/E14 reverse.
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ENG Structure and Transcripts HHT families (ﬁg. 3). These defects included four dele-
tions and three point mutations, one shared by two fami-As a ﬁrst step toward identiﬁcation of HHT muta-
lies.tions, the ENG structure (ﬁg. 2) and RNA transcripts
Southern blot analyses of the proband in family Rwere characterized. Distances between exons were as-
(ﬁg. 4Ai) demonstrated a mutant allele that deletedsessed by use of long PCR (only the ﬁrst and second
Ç1.5 kb of DNA, spanning exon 8 and the ﬂankingintrons were not spanned by this method) and were
intronic sequences. The introns ﬂanking exon 8 werereﬁned by restriction mapping of P1 clone 22. ENG
found to contain alu sequences (ﬁg. 2, arrows), the sitespans Ç35 kb and is organized into 15 exons. ENG
and orientation of which could account for the dele-sequences previously assigned (McCallister et al. 1994)
tion by homologous recombination, as has been de-to exons 8 and 9 were found to be organized into three
scribed for other sequences containing alu repeatsexons. Exon 8 contains nucleotides 1391–1415. Exon
(Shovlin et al. 1994b). The deletion in family R results9 sequences are contained in two exons, here designated
in a mutant ENG transcript (ﬁg. 5Aii) that lacks exon‘‘9A’’ and ‘‘9B.’’ Exon 9B contains only 39 bp. Compari-
8 and, because of a frameshift, predicts the incorpora-son of ENG mRNA transcripts and genomic structure
tion of 25 novel amino acids before a TGA stop codondemonstrated that the long (L-ENG) and short (S-ENG)
is reached in exon 9A.forms of ENG protein (Bellon et al. 1993) result from
An ENG deletion was also found in family I. Southernalternative splicing of the ﬁnal intron between exons 13
blot analyses identiﬁed a large deletion extending fromand 14 (designated ‘‘13A’’).
intron 8, deleting exons 9A–14 (ﬁg. 4B). Although theTwo polymorphisms were mapped during these studies.
3 boundary of the deletion has not been deﬁned, itThe RFLPs in AK1 (Puffenberger and Francomano 1991)
does not extend to an ENG CA repeat located õ60were identiﬁed on the same EcoRI fragment as was ENG
kb distant, since affected family members demonstrateexon 1. Furthermore, a novel CA-dinucleotide repeat was
heterozygosity at this polymorphism. In addition to pro-located õ60 kb from ENG exon 14.
tein-encoding sequences, this mutation deletes the ENG
ENG Mutations polyadenylation addition site, thereby predicting that no
stable mRNA species would result. RT-PCR (data notENG was analyzed in probands from 28 HHT fami-
lies, by three independent methods: Southern blot analy- shown) of samples from affected family members failed
to amplify product from the mutant allele; only wild-ses, genomic ampliﬁcation and sequencing of each exon,
and reverse transcription of ENG mRNA and PCR am- type ENG cDNA was detected; that is, ENG mRNA
was reversed transcribed (see Material and Methods),pliﬁcation ofENG cDNA (rt-PCR) for sequence analysis
(Methods). Novel mutations were identiﬁed in eight PCR ampliﬁed, and cloned into a plasmid vector, and
the clones were characterized by nucleotide-sequence
analysis; no mutant ENG cDNA clones were detected,
and only wild-type ENG cDNA clones were found.
The deletion mutation in family B was ﬁrst detectedTable 1
as a short cDNA species: sequencing of this product
LOD Scores Reﬂecting Linkage between ENG and HHT demonstrated a deletion of 152 nucleotides encoded
in Eight Families
in exon 2 (ﬁg. 4Ci). This deletion produces a frameshift
that predicts the incorporation of 27 novel amino acidsLOD SCORE AT u Å
before a TGA stop codon is reached in exon 3. South-
FAMILY MARKERa .00 .01 .05 ern blot analyses of DNAs (ﬁg. 4Cii) from affected but
not from unaffected members of family B demon-
A D9S60 3.64 3.64 3.54
strated reduced hybridization to an ENG exon 2F D9S61 1.79 1.75 1.61
probe, compared with an ADA probe (Shovlin et al.W D9S61 3.29 3.24 3.02
B SPTAN 1.46 1.43 1.33 1994b) derived from chromosome 20, indicating that
S D9S60 03.79 01.75 0.89 the exon skip occurred because of a genomic deletion
T D9S61 04.13 02.06 01.19 spanning exon 2.
V D9S315 02.58 01.4 0.23
A 21-bp deletion in exon 5 (ﬁg. 4D) was detected inY D9S61 06.12 03.95 01.98
affected members of family Q. This in-frame deletion
NOTE.—HHT is linked to ENG in families A, F, W, and B and is removes cDNA nucleotides 855–875, which encode
unlinked to it in families S, T, V, and Y. The linkage relationships amino acids Arg-Thr-Leu-Glu-Trp-Arg-Pro. Four of
between HHT and ENG in families A, F, and T have been described these residues are highly conserved ENG transcripts se-
elsewhere (Shovlin et al. 1994a).
quenced from man, mouse, and pig (ﬁg. 6).a Markers were selected because they were informative in the fami-
The HHT disease haplotype (loci D9S315/ENG/lies. All markers are õ2 cM of ENG (Shovlin et al. 1995a; authors’
unpublished data). SPTAN, õ2 cM from ENG) segregating in families F
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Figure 3 Pedigrees of HHT families. Individuals are designated by sex, disease status (blackened symbols denote affected individuals,
and unblackened symbols denote unaffected individuals), and pedigree numbers. Deceased individuals are denoted by diagonal slashes. M
Å presence of ENG mutation causing HHT. Asterisks (*) denote living individuals who did not participate in genetic studies.
and N was the same, suggesting that these two families, cryptic splice site shares only 5 of the 11 residues of the
optimal donor splice-site consensus sequence, C/AAG-which are of similar southern-English ancestry and cur-
rently reside Ç100 miles apart, share a founding muta- GTT/ATGTAT (Zhang et al. 1995). However, an adja-
cent polypurine tract comprising nucleotides 1397–tion that arose in a shared ancestor. This hypothesis was
conﬁrmed by sequence analyses of ENG in the probands 1406 may enhance the use of this splicing site (Laviguer
et al. 1993; Manley and Tacke 1996) and thereby ac-of families F and N, which demonstrated that these indi-
viduals shared the same HHT-causing mutation. A GrA count for the absence of transcripts that lack exon 8
sequences.substitution was identiﬁed in the donor splice signal of
intron 8 (ﬁg. 4A) in affected individuals from both fam- A donor splice-site mutation was also detected in
family O. The ArG substitution in intron 3 was identi-ily F and family N. Although this gene defect might
generate several ENG transcripts because of exon skip- ﬁed by genomic sequencing (data not shown). Al-
though there is a potential cryptic donor splice siteping and/or use of cryptic splice sites, only one abnormal
cDNA species was ampliﬁed by PCR. The mutant, trun- upstream (nucleotides 560–571) that contains 7 of 11
residues of the optimal donor splice-site consensus se-cated ENG transcript lacked 24 nucleotides (1391–
1415) that encode eight poorly conserved amino acids quence, this did not appear to be active. RT-PCR using
primers C2 and C7 ampliﬁed only one mutant tran-(ﬁg. 6). These nucleotides, encoded in exon 8 (ﬁg. 1),
are deleted from the mutant cDNA sequence by activa- script, which lacked exon 3 (ﬁg. 4B). This mutant tran-
script predicts the loss of 47 amino acids from thetion of a cryptic splice site within exon 8, located 24
nucleotides upstream from the natural splice site. This translated protein.
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Figure 4 ENG deletions causing HHT in four families. DNA samples from affected individuals (lanes A) and unaffected individuals
(lanes /) were analyzed. Ai, HindIII digest of genomic DNA from individuals in family R. A Southern blot ﬁlter probed with PCR product
which spans exon 7. The shorter HindIII fragment is due to a deletion, which also created a novel PstI fusion fragment of 2 kb, by the
apposition of the truncated fragment containing exons 7 and 8 (5) to a fragment normally 3 of exon 8. Aii, C8/C12 RT-PCR (using primers
C8 and C12), demonstrating the wild-type product (502 bp) and a shorter product (363 bp) that lacked all exon 8 sequence. B, Genomic
Southern blot of samples from family I. EcoRI-digested DNA was probed with PCR products containing exon 8 (E8 forward/E8 reverse) and
exon 14 (E13 forward/E14 reverse). Although these exons lie on the same EcoRI fragment, in DNA from affected individuals a small fragment
detected by the exon 8 probe was not detected by the exon 14 probe, indicating that the deletion includes exon 14. The larger XbaI fragment
deﬁnes the 5 extent of the deletion, since intron 8 normally contains an XbaI site (data not shown). Ci, Genomic Southern blot of samples
from family B. DNA samples were digested with HindIII, and the ﬁlter was probed sequentially with PCR products containing a part of the
5 region of ADA on chromosome 20 (Shovlin et al. 1994b) and with exon 2 (E2 forward and reverse). Quantitative assessment of these and
additional data not illustrated, by use of a Molecular Dynamics PhosphorimagerTM (model 4255) and the ImageQuantTM program, conﬁrmed
that the ENG exon 2 bands from affected individuals were half the predicted intensity, compared with those in equally loaded wild-type
controls. Cii, RT-PCR (using primers C2 and C7), which ampliﬁed the wild-type product (603 bp) and a shorter fragment (310 bp) that lacked
exon 2 nucleotides. D, Exon 5 ampliﬁed from genomic DNA in samples from family Q (E5 forward and reverse). The 283-bp product results
from a 21-bp genomic deletion.
Affected members of family AA were heterozygous than 100 normal chromosomes were screened for each
of these seven ENG defects; no defects were detected.for a CrT substitution at residue 792 in exon 4 (ﬁg.
4A). This mutation changes the normal CGA codon We conclude that these ENG defects caused HHT in
each family.(encoding arginine) to a TGA stop codon. mRNAs
derived from either peripheral blood lymphocytes or Two additional sequence variants were identiﬁed.
These appear to be rare polymorphisms in ENG, ratherEBV-transformed lymphoblast cell lines derived from
two affected family members were ampliﬁed by RT- than disease-causing mutations. Members of one family
were heterozygous for the transition C295T, which al-PCR using poly(dT)14 and primer C14 (ﬁg. 1). The
ampliﬁed PCR product was subjected to sequence ters a nonconserved codon, in exon 1, from ACG (threo-
nine) to ATG (methionine). However, this allele did notanalysis to determine the ratio of mutant and wild-
type cDNA. In three independent analyses, only wild- segregate with disease. In another family, C401T was
present only in an affected father and daughter but didtype sequence was detected. Absence of the mutated
transcript may reﬂect early degradation of mRNAs not predict an amino acid substitution. Two further si-
lent nucleotide variations were found to be polymorphiccontaining nonsense codons (Belgrader and Maquat
1994), especially because residues 758–771 (tgctga- in the normal population: G488A in exon 2 (in 11% of
the control population) and C1310T in exon 8 (in 5%gctgaatg) have homology to a Saccharomyces cerevis-
iae sequence that is responsible for premature mRNA of the control population).
Southern blot analyses and sequence analyses of ENGdegradation (Zhang et al. 1995).
Only one ENG defect was identiﬁed in affected exons and cDNAs failed to identify ENG mutations in
two families (A and W), although, in each of them,members from these eight families. There was com-
plete concordance between the clinical status of family genetic studies indicated linkage between HHT and the
ENG locus (LOD scores ú3, u Å 0). We suspect thatmembers and the presence of each ENG defect. More
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Figure 5 ENG point mutations causing HHT in four families. A, ENG transcripts, ampliﬁed by use of primers C8 and C12 (ﬁg. 1),
from affected members of families F and N, revealing the normal sized product (293 bp) and a truncated product (269 bp) resulting from a
GrA splice-site mutation and use of a cryptic splice site. The genomic mutation is indicated, and the polypurine tract is underlined. B, ArG
splice site mutation identiﬁed in family O, which produces a truncated transcript that lacks exon 3. RT-PCR (using primers C2 and C7)
ampliﬁed the wild-type 520-bp product and the mutant 379-bp product. C, T lane of dideoxy sequence reactions, for DNA samples from three
affected members of family AA and for one control sample. Note the absence of the band in the T lane (residue 792) in the control sample.
an undetected 5 deletion, possibly involving ENG pro- from both families were heterozygous for the ENG CA
repeat (data not shown).moter sequences, may account for HHT in family W,
since affected members have only one allele at each AK1
Clinical Datapolymorphism. Large deletions that might mutate im-
portant 3 ENG sequences appear to be an unlikely The clinical manifestations of HHT (table 2) that are
associated with these novel ENG mutations were com-cause of HHT in either family, since affected members
Figure 6 Human, mouse, and pig ENG amino acid sequences in the vicinity of HHT mutations (the sites of the stop codons in exons 3
and 9A, which predict truncated proteins, are not illustrated). The human ENG cDNA is illustrated as in ﬁgure 1 and deﬁnes the sites of
encoded cysteine residues implicated in dimerization (C), as well as the position of the transmembrane domain (TM).
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pared. Telangiectases and nosebleeds, often commenc- missed ENG mutations in some families. Taken to-
gether, these data suggest that ENG mutations maying in childhood, were common manifestations of dis-
ease in the 30 affected individuals from these eight HHT cause as much as 50% of HHT.
Previous studies have suggested that PAVMs fre-families. Seven individuals from ﬁve families had docu-
mented gastrointestinal involvement. Twenty-one indi- quently occurred in HHT patients whose disease was
caused by ENG mutations (Guttmacher et al. 1995).viduals from eight families had PAVMs. Although a
larger series (Shovlin et al. 1995b) suggested an in- In the present study, HHT patients with PAVMs were
identiﬁed in 19 unrelated families in which no ENGcreased incidence of PAVMs in female patients, the pres-
ence of PAVMs in affected men or women did not statis- mutations were detected, including affected members of
4 families whose disease did not segregate with the ENGtically differ in this study group. Three women, from
families F, I, and O, had pregnancy-related deterioration locus (table 1). Among the HHT patients studied here,
the incidence of PAVMs was higher in those whose dis-in the pulmonary vascular bed. Parameters analyzed by
analysis of variance (computed by use of StatviewTM ease was caused by ENG mutations than in those whose
disease was caused by mutations in other HHT diseaseMII) did not demonstrate differences—with respect to
age of presentations, subjective severity of nose bleeds genes.
Characterization of HHT-causing mutations providesor telangiectasia, or PAVMs—in HHT caused by the
seven different ENG mutations. insights into the molecular mechanism by which ENG
mutations cause HHT, and it may provide novel ap-The incidence of PAVMs in individuals whose disease
was caused by ENG mutations and in individuals whose proaches for therapeutic development. ENG is expressed
as a disulﬁde-linked dimer on endothelial cells. Pre-disease was not caused by ENG mutations was assessed
(table 2 and data not shown). Forty-one percent (23/56) viously reported mutations predicted defects in the pep-
tide’s extracellular domain, and a dominant negativeof HHT patients with ENG mutations had PAVMs,
whereas a signiﬁcantly smaller fraction, 14% (5/35), of mechanism has been proposed (McAllister et al. 1995)
to account for the pathogenesis of HHT. ENG deﬁciencyHHT patients in whom linkage analyses indicated non-
ENG mutations had PAVMs (P õ .01). has also been postulated to cause HHT, via a somatic,
second event (a ‘‘two-hit’’ mechanism; McAllister et al.
Discussion 1994). The data presented here demonstrate that muta-
tions that block ENG mRNA production can also causeWe have characterized the structure of ENG, deﬁned
the alternative splice variants that result in L-ENG and HHT. We conclude that haploinsufﬁciency of ENG can
cause HHT.S-ENG, and identiﬁed seven novel mutations that cause
HHT in eight families. Two point mutations result in The lack of correlation between genotype and clinical
manifestations of HHT supports the haploinsufﬁciencyaberrant splicing. A third, which would predict prema-
ture termination in exon 4, was not detected in cDNA model. If a dominant-negative mechanism accounted for
HHT, different mutations might be expected to be asso-preparations. Four deletions were also identiﬁed, and at
least one of these appears to function as a null allele. ciated with discrete clinical phenotypes. In contrast, if
HHT mutations result in ENG haploinsufﬁciency, itThese seven mutations have not been described else-
where, and we did not detect in the 32 HHT study would be surprising if clinical features were mutation
speciﬁc. In our series, the clinical phenotypes (table 2)families any of the ENG defects reported elsewhere
(McAllister et al. 1994, 1995). A greater diversity of caused by seven mutations were not statistically differ-
ent. Furthermore, the greatest trend toward differencesdifferent types of ENG mutations were identiﬁed in the
present study than in previous studies, presumably be- in visceral involvement was observed between families
F and N, which share the identical ENG mutation.cause of the comprehensive screening methods that we
applied, rather than because of differences in patient How does the loss of ENG protein result in HHT? The
majority of vascular beds in which ENG is expressedpopulations. cDNA analyses proved to be the most in-
formative approach and identiﬁed ﬁve of the seven mu- (Cheifetz et al. 1992) appear to develop normally in
HHT patients, implying that the quantitative require-tations; three of seven mutations would have been en-
tirely missed without cDNA screening or without careful ment for ENG varies spatially and, perhaps, temporally.
ENG binds TGF-b1 and -b3 (Cheifetz et al. 1992) andanalysis for genomic deletions. Despite genomic and
cDNA analyses, mutations were deﬁned in only two of can modify a subset of cellular responses to TGF-b1,
including the inhibition of cellular proliferation and thefour families with HHT linked to ENG. Families with
HHT linked to ENG in which mutations were not de- stimulation of extracellular adhesion molecules (Lastres
et al. 1996). There is a wide range of known roles fortected may have defects either in regulatory regions of
ENG or in intronic sequences. We have demonstrated the ENG ligands, which in the vasculature include devel-
opment (Dickson et al. 1995; Kaartinen et al. 1995),ENG mutations in at least one-quarter of the HHT pro-
bands studied here and suggest that we could have angiogenesis (Koh et al. 1995), and vascular repair (Ma-
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genesis in transforming growth factor-b1 knock out mice.dri et al. 1992). Future studies of the consequences of
Development 121:1845–1854ENG mutations on these processes, as well the develop-
Edwards A, Civitello A, Hammond HA, Caskey CT (1991)ment of an animal model for HHT, may provide crucial
DNA typing and genetic mapping with trimeric and tetra-insights into the mechanisms by which TGF-b signaling
meric tandem repeats. Am J Hum Genet 49:746–756maintains the structural integrity of the vascular bed.
Gougos A, Letarte M (1990) Primary structure of endoglin,
an RGD-containing glycoprotein of human endothelial cells.
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